Drug interventions for prevention of COVID-19 progression to severe disease in outpatients : a systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVES: To assess the effects of interventions authorised by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) for prevention of COVID-19 progression to severe disease in outpatients.
SETTING: Outpatient treatment.
PARTICIPANTS: Participants with a diagnosis of COVID-19 and the associated SARS-CoV-2 virus irrespective of age, sex and comorbidities.
INTERVENTIONS: Drug interventions authorised by EMA or FDA.
PRIMARY OUTCOME MEASURES: Primary outcomes were all-cause mortality and serious adverse events.
RESULTS: We included 17 clinical trials randomising 16 257 participants to 8 different interventions authorised by EMA or FDA. 15/17 of the included trials (88.2%) were assessed at high risk of bias. Only molnupiravir and ritonavir-boosted nirmatrelvir seemed to improve both our primary outcomes. Meta-analyses showed that molnupiravir reduced the risk of death (relative risk (RR) 0.11, 95% CI 0.02 to 0.64; p=0.0145, 2 trials; very low certainty of evidence) and serious adverse events (RR 0.63, 95% CI 0.47 to 0.84; p=0.0018, 5 trials; very low certainty of evidence). Fisher's exact test showed that ritonavir-boosted nirmatrelvir reduced the risk of death (p=0.0002, 1 trial; very low certainty of evidence) and serious adverse events (p<0.0001, 1 trial; very low certainty of evidence) in 1 trial including 2246 patients, while another trial including 1140 patients reported 0 deaths in both groups.
CONCLUSIONS: The certainty of the evidence was very low, but, from the results of this study, molnupiravir showed the most consistent benefit and ranked highest among the approved interventions for prevention of COVID-19 progression to severe disease in outpatients. The lack of certain evidence should be considered when treating patients with COVID-19 for prevention of disease progression.
PROSPERO REGISTRATION NUMBER: CRD42020178787.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
BMJ open - 13(2023), 6 vom: 20. Juni, Seite e064498 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Petersen, Johanne Juul [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.09.2023 Date Revised 06.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2022-064498 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358413419 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358413419 | ||
| 003 | DE-627 | ||
| 005 | 20231226210528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2022-064498 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358413419 | ||
| 035 | |a (NLM)37339844 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Petersen, Johanne Juul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug interventions for prevention of COVID-19 progression to severe disease in outpatients |b a systematic review with meta-analyses and trial sequential analyses (The LIVING Project) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.09.2023 | ||
| 500 | |a Date Revised 06.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVES: To assess the effects of interventions authorised by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) for prevention of COVID-19 progression to severe disease in outpatients | ||
| 520 | |a SETTING: Outpatient treatment | ||
| 520 | |a PARTICIPANTS: Participants with a diagnosis of COVID-19 and the associated SARS-CoV-2 virus irrespective of age, sex and comorbidities | ||
| 520 | |a INTERVENTIONS: Drug interventions authorised by EMA or FDA | ||
| 520 | |a PRIMARY OUTCOME MEASURES: Primary outcomes were all-cause mortality and serious adverse events | ||
| 520 | |a RESULTS: We included 17 clinical trials randomising 16 257 participants to 8 different interventions authorised by EMA or FDA. 15/17 of the included trials (88.2%) were assessed at high risk of bias. Only molnupiravir and ritonavir-boosted nirmatrelvir seemed to improve both our primary outcomes. Meta-analyses showed that molnupiravir reduced the risk of death (relative risk (RR) 0.11, 95% CI 0.02 to 0.64; p=0.0145, 2 trials; very low certainty of evidence) and serious adverse events (RR 0.63, 95% CI 0.47 to 0.84; p=0.0018, 5 trials; very low certainty of evidence). Fisher's exact test showed that ritonavir-boosted nirmatrelvir reduced the risk of death (p=0.0002, 1 trial; very low certainty of evidence) and serious adverse events (p<0.0001, 1 trial; very low certainty of evidence) in 1 trial including 2246 patients, while another trial including 1140 patients reported 0 deaths in both groups | ||
| 520 | |a CONCLUSIONS: The certainty of the evidence was very low, but, from the results of this study, molnupiravir showed the most consistent benefit and ranked highest among the approved interventions for prevention of COVID-19 progression to severe disease in outpatients. The lack of certain evidence should be considered when treating patients with COVID-19 for prevention of disease progression | ||
| 520 | |a PROSPERO REGISTRATION NUMBER: CRD42020178787 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a general medicine (see internal medicine) | |
| 650 | 4 | |a primary care | |
| 650 | 4 | |a public health | |
| 650 | 4 | |a quality in health care | |
| 650 | 7 | |a molnupiravir |2 NLM | |
| 650 | 7 | |a YA84KI1VEW |2 NLM | |
| 650 | 7 | |a nirmatrelvir |2 NLM | |
| 650 | 7 | |a 7R9A5P7H32 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Jørgensen, Caroline Kamp |e verfasserin |4 aut | |
| 700 | 1 | |a Faltermeier, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Siddiqui, Faiza |e verfasserin |4 aut | |
| 700 | 1 | |a Feinberg, Joshua |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, Emil Eik |e verfasserin |4 aut | |
| 700 | 1 | |a Torp Kristensen, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Juul, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Holgersson, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, Niklas |e verfasserin |4 aut | |
| 700 | 1 | |a Bentzer, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Thabane, Lehana |e verfasserin |4 aut | |
| 700 | 1 | |a Kwasi Korang, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Klingenberg, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Gluud, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Jakobsen, Janus C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2012 |g 13(2023), 6 vom: 20. Juni, Seite e064498 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:6 |g day:20 |g month:06 |g pages:e064498 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2022-064498 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 6 |b 20 |c 06 |h e064498 | ||